Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.620 +0.020 (+1.25%)
Streaming Delayed Price Updated: 12:59 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK ↗
NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 
Via Stocktwits
News headline image
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
AUCATZYL® will be available through routine commissioning by the UK National Health Service (NHS) 
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
A Look at Autolus Therapeutics's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NASDAQ:SRPT),(NASDAQ:AUTL),(NASDAQ:ARCT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
News headline image
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INDP),(NYSE:CATX),(NASDAQ:SLS),(NASDAQ:AUTL EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
What 4 Analyst Ratings Have To Say About Autolus Therapeutics ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens ↗
CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.